Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Isofol Medical AB ( (SE:ISOFOL) ) just unveiled an announcement.
Isofol Medical AB has announced a fully guaranteed Rights Issue of approximately SEK 85 million, with an additional over-allotment issue of SEK 10 million proposed to accommodate potential oversubscription. This financial move is aimed at securing funds for an expanded Phase II study, with significant support from existing shareholders and strategic partner Solasia Pharma K.K., highlighting confidence in Isofol’s strategic direction and the potential of its lead drug, arfolitixorin.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company based in Gothenburg, Sweden, primarily focused on developing cancer treatments. The company is known for its work on arfolitixorin, a drug aimed at enhancing the efficacy of chemotherapy in cancer patients.
YTD Price Performance: -16.31%
Average Trading Volume: 342,680
Current Market Cap: SEK300.1M
See more data about ISOFOL stock on TipRanks’ Stock Analysis page.